Vigabatrin: An Effective antiepilepsy drug - Balancing the risk of visual dysfunction

Annals of Pharmacotherapy

Volumn 33, Issue 12, 1999, Pages 1367-1368

  Krauss, Gregory L ^a   Miller, Neil R ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

VIGABATRIN;

ANTICONVULSANT THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ELECTRORETINOGRAM; EPILEPSY; FOCAL EPILEPSY; HUMAN; NOTE; PRIORITY JOURNAL; RETINA DISEASE; VISUAL FIELD DEFECT;

EID: 0033376943     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19308     Document Type: Note

References (13)

1. Gidal BE, Privitera MD, Sheth RD, Gilman JT. Vigabatrin: a novel therapy for seizure disorders. Ann Pharmacother 1999;33:1277-86.
2. Katz R. The domestic drug regulatory process: why time is of the essence. In: French JA, Dichter MA, Leppik IE, eds. New antiepileptic drug developments. Amsterdam: Elsevier Science, 1993:91-106.
3. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin (letter). BMJ 1997;314:180-1.
4. Mackenzie R, Klistorner A. Asymptomatic as well as symptomatic defects occur with vigabatrin (letter). BMJ 1998;316:233.
5. Harding GFA. Severe persistant visual field constriction associated with vigabatrin. BMJ 1998;316:232-3.
6. Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 1998;50:614-8.
7. Miller NR, Johnson MA, Paul SR, Girkin CA, Perry JD, Endres M, et al. Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings. Neurology 1999, in press.
8. Kalviainen R, Nousiainen I, Mantyjarvi M, Nikoskelainen E, Partanen J, Partanen K, et al. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology 1999;53:922-6.
9. Sankar R, Wasterlain CG. Is the devil we know the lesser of two evils? Vigabatrin and visual fields. Neurology 1999;52:1537-8.
10. Hauser WA, Annegers JF, Elveback LR. Mortality in patients with epilepsy. Epilepsia 1980;21:399-421.
11. Cramer JA, Fisher R, Ben-Menachem E, French J, Mattson RH. New antiepileptic drugs: comparison of key clinical trials. Epilepsia 1999;40: 590-600.
12. Beran R, Hung A, Plunkett M, Currie J, Sachinwalla T. Predictability of visual field defects in patients exposed to GABAergic agents, vigabatrin, or tiagabine (abstract). Neurology 1999;52(suppl 2):A249.
13. Kalviainen R, Nousiainen I, Mantyjarvi M, Riekkinen P. Absence of concentric visual field defects in patients with initial tiagabine monotherapy (abstract). Epilepsia 1999;40(suppl 2):A259.